1. By: Dr. Vahid Nikoui
Email: nikoui@razi.tums.ac.ir

5. *Milstein & Kohler in 1975
*Hybridoma
*Antibody-forming cells fused to immortal plasmacytoma
cells
*Hybrid cells that are stable and produce the required
antibody can be subcloned for mass culture for antibody
production

7. Antilymphocyte (ALG) and
antithymocyte (ATG) globulins
* Obtained from the serum of animals
* Steroid-resistant
acute rejection reaction and grave aplastic anemia
treatment, delayed hypersensitivity and the graft-versus-host disease
(GVHD)
* As an adjuvant in ciclosporin therapy
* Inhibit T lymphocytes and cause their lysis:
* Complement-mediated cytolysis
* Cell-mediated opsonization followed by removal of reticuloendothelial cells
from the circulation in the spleen and liver

8. *There are two preparations available to the market:
* Atgam ,obtained from horse serum
* Thymoglobuline obtained from rabbit serum
*High immunogenicity, acute reaction to the
treatment, fever and even anaphylaxis (type III)

9. *High dose (2g/kg)
*Decreased T-Helper and increased T-Suppressor
*In different autoimmune diseases

10. * Rh0(D) IgG
* Mother Rh- and fetus Rh+
* Labor, abortion or ectopic pregnancy (sensitization)
* Next pregnancy: Erythroblastosis (heamolytic)
* Rho Ab injection to mother 24-72 hrs after the labor of a
Rh+ newborn

11. *IGIV
*From selected donors
*Abs against viruses and toxins

13. *Directed towards exactly defined antigens
*Fewer side-effects

14. * Humanization
* Fc
* Murine
* -onab
* Humanized
* -umab or -zumab
* Chimeric
* -imab or -ximab
* Recombinant Pr attached to Abs
* -cept

17. * Murine anti-CD3
* Prevents T-cell activation and proliferation
* One of the most potent immunosuppressive substances
* To control the steroid- and/or polyclonal antibodies-resistant acute
rejection episodes
* Also used prophylactically in transplantations
* Inthe first few administrations this binding non-specifically activates
T-cells, leading to a serious syndrome 30 to 60 minutes later. It is
characterized by fever, myalgia, headache, and arthralgia.

18. *A recombinant Pr that attached to Fc part of
human IgG1
*Binds to CD2 on T cells
*Psoriasis

19. *Humanized antibody
*Binds to CD11a (α part of LFA-1) on T cells
*Prevents the interaction between LFA-1 and ICAM-1
on APCs
*Severe Psoriasis

20. *Humanized IgG1
*Binds to CD52 on B cells, T cells and NK
*Chorionic lymphocytic leukemia

21. *Chimeric IgG1
*Binds to CD20 on B cells
*Non-Hodgkin`s lymphoma

23. *Chimeric mouse/human antibody
*1998
*Binds to IL-2a receptor's α chain (CD25)
*Prophylaxis of the acute organ rejection after
kidney transplantation

24. *Humanized antibody
*1998
*Binds to IL-2a receptor's α chain (CD25)
*Prophylaxis of the acute organ rejection after
kidney transplantation

25. *Suppression of IL-1 and IL-6 and leukocyte
migration

26. *Completely Human IgG1
*Rheumatoid arthritis
*Toxicity: lymphoma

27. *A recombinant Pr that attached to Fc part of
human IgG1
*Rheumatoid arthritis
*Toxicity: lymphoma

28. *Chimeric IgG1
*Rheumatoid arthritis
*Crohn`s disease
*Toxicity: lymphoma

29. *A recombinant Pr that attached to Fc part of
human IgG
*Binds to CD80 or CD86 on APCs
*Inhibition of contact to CD28 on T cells
*Rheumatoid arthritis

30. *Humanized Ab against IgE
*Prevents IgE attachment to Fc receptors on basophils
and mast cells
*Prevents resealing of type I allergic mediators